NRx Pharma rises as FDA suggests broadening scope of bipolar disorder drug trial

NRX Pharmaceuticals

13/02/2023 14:05

** Shares of drug developer NRx Pharmaceuticals Inc  NRXP.O 
rise 4.5% to $1.17 premarket
    ** Co says the FDA in a meeting suggests broadening scope of
NRX-101, the co's drug to treat severe bipolar depression in
suicidal patients
    ** The regulator suggested expanding the study to include
chronic treatment of the indication, which could expand the
addressable patient population to ~7 mln individuals in the
United States - NRXP 
    ** The FDA also suggests to widen the development program
scope to include patients treated with stabilizing agents other
than ketamine
   ** Co is considering to expand its current mid-stage study
based on the FDA's guidance 
   ** The FDA also encouraged to request a Breakthrough Therapy
Planning Meeting for the drug - NRXP
    ** Stock down 58.5% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))